Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases Operations; A Brief Dispatch from ICPR
This week: MindMed continues to face troubles amidst shareholder activist situation; Onsero Therapeutics looks to skip the trip; Havn ceases operations; a brief dispatch from ICPR; and more…
Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics
This week: SF Decriminalizes Psychedelics, But What Does That Mean? and more…
Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics
This week: we take a deeper dive into that psilocybin for alcohol use disorder study; ARK Invest publishes analysis of psychedelics market; former MindMed CMO alleges fellow co-founder syphoned off IP; and more…
Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs
This week: Freedom Biosciences raises $10m in a seed round; DEA abandons plan to schedule DOI and DOC; analysis of Oregon psilocybin services opt-out activity; and more…
Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains ‘Meme Stock’ Status; atai ‘Streamlilnes’ Pipeline; California Decrim. Bill Gutted
This week: MindMed has become a meme stock; Mydecine looks set to cease operations soon; atai becomes latest psychedelics co. to ‘streamline’ pipeline; and more…
Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed CMO Turns Activist Shareholder; California Decrim. Bill Tentatively Clears Hurdle
This week: we take a look at the lawsuit brought against Compass Pathways by Terran Biosciences; Compass says a tweet describing Terran as “slime” was due to a hack; former MindMed CMO turns activist shareholder; and more…